U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H26N4O2.CH4O3S
Molecular Weight 462.562
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LINAPRAZAN MESYLATE

SMILES

CS(O)(=O)=O.CC1=C(C)N2C=C(C=C(NCC3=C(C)C=CC=C3C)C2=N1)C(=O)NCCO

InChI

InChIKey=QCHUWMQLRFKFDK-UHFFFAOYSA-N
InChI=1S/C21H26N4O2.CH4O3S/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25;1-5(2,3)4/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H26N4O2
Molecular Weight 366.4567
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Linaprazan is a member of a new group of acid-suppressing agents, which unlike proton pump inhibitors, act through potassium-competitive inhibition of the H+,K+-ATPase located in the apical membrane of parietal cells. It displayed rapid inhibition of acid production and had a prolonged, dose-dependent duration of effect. Linaprazan reduced porcine renal Na(+),K(+)-ATPase activity by 9+/-2%, demonstrating a high selectivity for H(+),K(+)-ATPase. It provided similar efficacy to esomeprazole in terms of esophagitis healing and heartburn control.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.13 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression.
2012 Sep
Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression.
2014 Sep
Patents

Sample Use Guides

25, 50, 75 mg given once daily for 4 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:34:28 GMT 2023
Edited
by admin
on Fri Dec 15 15:34:28 GMT 2023
Record UNII
5P098C89CG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LINAPRAZAN MESYLATE
Common Name English
AZD-0865 MESYLATE
Code English
AR-H044277AW
Code English
AZD-0865 MESILATE
Common Name English
LINAPRAZAN MESILATE
Common Name English
Code System Code Type Description
FDA UNII
5P098C89CG
Created by admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
PRIMARY
PUBCHEM
11248232
Created by admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
PRIMARY
SMS_ID
300000027093
Created by admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
PRIMARY
CAS
855998-67-3
Created by admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY